Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer

被引:57
作者
Gopal, R
Starkschall, G
Tucker, SL
Cox, JDC
Liao, ZX
Hanus, M
Kelly, JF
Stevens, CW
Komaki, R
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2003年 / 56卷 / 01期
关键词
radiotherapy; pulmonary toxicity; lung cancer; diffusion capacity;
D O I
10.1016/S0360-3016(03)00077-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the effects of chemoradiation on objective tests of pulmonary function. Methods and Materials: One hundred lung cancer patients treated in five protocols between 1992 and 2000 with combinations of thoracic radiotherapy (RT) and chemotherapy were evaluated with pre- and post-RT pulmonary function tests. The pulmonary function tests were analyzed for changes in measures of obstruction (forced expiratory volume in 1 s per unit of vital capacity [FEV1/VC]), restriction (total lung capacity [TLC]), and diffusing capacity (diffusing capacity for carbon monoxide [DLCO]). The use and timing of chemotherapy and RT, as well as patient, tumor, and treatment factors, were evaluated using univariate and multivariate analyses. Results: No treatment or patient factors were significantly associated with changes in FEV1/VC. Chemotherapy with RT, compared with RT alone, was associated with a lower post-RT TLC (92% vs. 107%,p = 0.002). Nodal status (N2-N3 vs. N1)tumor location (central vs. peripheral), use of greater than or equal to6 treatment fields, and tumor volume greater than or equal to100 cm(3) were also associated with a significantly lower post-RT TLC. On univariate analysis, the use of any chemotherapy (p = 0.029) and the use of concurrent vs. sequential chemotherapy (p = 0.028) were predictive of a lower post-RT DLCO. Patient age greater than or equal to60 years, nodal status (N2-N3 vs. N0-N1), tumor volume greater than or equal to100 cm(3), tumor location (central vs. peripheral), and use of greater than or equal to6 treatment fields were also associated with a significantly lower post-RT DLCO. The fractional volume of irradiated normal lung correlated with the decrease in DLCO (p <0.001), with a 1.3% DLCO decline for each 1% of total lung volume that received >20 Gy. Conclusion: The addition of chemotherapy to RT significantly exacerbates the post-RT decrease in TLC and DLCO. The greatest decrease in DLCO occurs in patients treated with concurrent chemoradiation. (C) 2003 Elsevier Inc.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 50 条
[21]   Molecular predictors of chemotherapy response in non-small-cell lung cancer [J].
Gray, Jhanelle ;
Simon, George ;
Bepler, Gerold .
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (04) :545-549
[22]   Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer:: Recent developments in combination chemotherapy and radiotherapy [J].
Gralla, R ;
Harper, P ;
Johnson, S ;
Delgado, FM .
ANNALS OF ONCOLOGY, 1999, 10 :47-51
[23]   Treatment of brain metastases from non-small-cell lung cancer (NSCLC): radiotherapy [J].
Zabel, A ;
Debus, A .
LUNG CANCER, 2004, 45 :S247-S252
[24]   The Value of Induction Chemotherapy for Survival in Patients with Non-small Cell Lung Cancer Treated with Radiotherapy [J].
Holgersson, Georg ;
Sandelin, Martin ;
Hoye, Even ;
Bergstrom, Stefan ;
Henriksson, Roger ;
Ekman, Simon ;
Nyman, Jan ;
Helsing, Martin ;
Friesland, Signe ;
Brodin, Ola ;
Holgersson, Margareta ;
Lundstrom, Kristina Lamberg ;
Janson, Christer ;
Ekberg, Lars ;
Morth, Charlotte ;
Blystad, Thomas ;
Ewers, Sven-Borje ;
Loden, Britta ;
Bergqvist, Michael .
ANTICANCER RESEARCH, 2012, 32 (04) :1339-1346
[25]   Safety and feasibility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients [J].
Fiorica, F. ;
Cartei, F. ;
Ursino, S. ;
Stefanelli, A. ;
Zagatti, Y. ;
Berretta, S. ;
Figura, S. ;
Maugeri, D. ;
Zanet, E. ;
Sparta, D. ;
La Morella, C. ;
Tirelli, U. ;
Berretta, M. .
ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2010, 50 (02) :185-191
[26]   Effects of bevacizumab combined with chemotherapy and radiotherapy on advanced non-small-cell lung cancer and on the expression of TPO and P-selectin [J].
Liu, Huiling ;
Liu, Yi ;
Li, Juanjuan .
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (03) :1361-1369
[27]   Elderly patients treatment with non-small-cell lung cancer [J].
Kowalski, Dariusz M. ;
Krzakowski, Maciej .
ONCOLOGY IN CLINICAL PRACTICE, 2012, 8 (01) :29-35
[28]   Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy [J].
Ball, D ;
Smith, J ;
Wirth, A ;
Mac Manus, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04) :1007-1013
[29]   Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer [J].
Umemura, Shigeki ;
Yamane, Hiromichi ;
Suwaki, Toshimitsu ;
Katoh, Tsutomu ;
Yano, Takuya ;
Shiote, Yasuhiro ;
Takigawa, Nagio ;
Kiura, Katsuyuki ;
Kamei, Haruhito .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (10) :1469-1475
[30]   Quality of Life in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Palliative Chemotherapy [J].
Daroszewski, Cyryl ;
Stasiewicz, Malgorzata ;
Jazwinska-Tarnawska, Ewa ;
Rachwalik, Anna ;
Mura, Ewa ;
Luboch-Kowal, Joanna ;
Drys, Andrzej ;
Bogucki, Zdzislaw A. ;
Brzecka, Anna .
ADVANCES IN PULMONARY MEDICINE: RESEARCH AND INNOVATIONS, 2019, 1160 :11-18